J&J (JNJ) subject of $1.1 billion penalty in Risperdal trial in Arkansas
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) subject of $1.1 billion penalty in Risperdal trial in Arkansas.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- China semiconductor equipment imports grow 9% in July, Barclays comments
- e-commerce stocks split as Rosenblatt favors Etsy, eBay; Chewy rated neutral
Create E-mail Alert Related Categories
FDA, General News, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
